New Blood Test Score Identifies Alcohol-Driven Fatty Liver Disease

Researchers at the University of California San Diego School of Medicine have developed a new blood test score, called the MetALD-ALD Prediction Index (MAPI), designed to identify when fatty liver disease is caused by excessive alcohol use. This crucial distinction is often overlooked in routine medical care.

The study, published in Gastroenterology on February 25, 2026, indicates that MAPI can assist clinicians in determining if liver injury is alcohol-driven rather than metabolically driven. This provides clearer guidance for when additional alcohol testing is necessary.

How MAPI Works

The MAPI tool simplifies the diagnostic process by leveraging readily available data:

• It utilizes five standard laboratory values typically collected during primary care and liver clinic visits.
• MAPI estimates the likelihood of alcohol-related liver injury in individuals with fatty liver disease, even when patients underreport alcohol consumption.
• This early identification can facilitate timely intervention, lifestyle modifications, and personalized treatment.

Rohit Loomba, MD, a senior author of the study, stated that the score offers a simple and accessible method to uncover hidden alcohol-related liver injury, potentially leading to improved long-term health outcomes for patients.

Study Scope and Impact

The research underpinning MAPI's development was extensive:

• The study analyzed over 500 adults in the San Diego region and approximately 1,800 individuals in Sweden, demonstrating its broad applicability.
• MAPI demonstrated superior performance compared to existing blood tests and can help determine the need for more advanced alcohol testing, such as phosphatidylethanol (PEth), which can be costly or unavailable.

Fatty liver disease affects nearly one in three adults globally, stemming from various causes, including metabolic factors (e.g., obesity, diabetes) and alcohol consumption. Undiagnosed alcohol-driven liver damage can progress silently, potentially leading to hospitalization and preventable deaths.

Researchers suggest that MAPI could be particularly beneficial in primary care settings, where most cases of fatty liver disease are first identified. The tool is expected to enhance patient counseling by providing a clearer understanding of their condition, thereby reducing stigma and encouraging open discussions about alcohol use.

Federica Tavaglione, MD, PhD, the study's first author, noted that MAPI's reliance on existing lab values allows for immediate implementation without increased cost or complexity for clinics. The research team plans to integrate MAPI into large observational studies and future clinical trials to further expand its potential for improving liver disease detection and patient care.